fda warning letters compounded semaglutide tirzepatide 2025 issued 25 to telehealth companies for false and misleading claims about GLP-1 products. Unlike FDA-approved drugs, these products have not been proven to be safe, effective, or of US FDA sends 25 letters

Buse highlighted a significant philosophical shift toward earlier and more routine use of glucagon-like peptide-1 (GLP-1) receptor agonists and sodium-glucose cotransporter 2 (SGLT-2) inhibitors, noting that the updated guidance explicitly recommends considering these agents from the point of a type 2 diabetes (T2D) diagnosis, given their role as disease-modifying therapies

As one of the most effective weight loss drugs available, semaglutide GLP-1 can lead to significant results, but its important to understand that drastic changes wont occur overnight

PubMed, Belenky, Michael A., et al

A Flexible Spending Account (FSA) is similar but is usually offered through an employer